Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cecilia Pozzi

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Antimicrobial Agents and Chemotherapy|December 25, 2019
VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in <i>Enterobacterales</i> and Pseudomonas aeruginosaJodie C Hamrick, Jean-Denis Docquier, Tsuyoshi Uehara, et al.
Journal of Medicinal Chemistry|December 11, 2020
Discovery of <b>ANT3310</b>, a Novel Broad-Spectrum Serine β-Lactamase Inhibitor of the Diazabicyclooctane Class, Which Strongly Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacterales and <i>Acinetobacter baumannii</i>David T Davies, Simon Leiris, Magdalena Zalacain, et al.
Journal of Medicinal Chemistry|November 30, 2022
Optimization of 1,2,4-Triazole-3-thiones toward Broad-Spectrum Metallo-β-lactamase Inhibitors Showing Potent Synergistic Activity on VIM- and NDM-1-Producing Clinical IsolatesAlice Legru, Federica Verdirosa, Yen Vo-Hoang, et al.
ACS Infectious Diseases|August 14, 2020
ANT2681: SAR Studies Leading to the Identification of a Metallo-β-lactamase Inhibitor with Potential for Clinical Use in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing <i>Enterobacteriaceae</i>David T Davies, Simon Leiris, Nicolas Sprynski, et al.
ACS Infectious Diseases|November 15, 2018
SAR Studies Leading to the Identification of a Novel Series of Metallo-β-lactamase Inhibitors for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections That Display Efficacy in an Animal Infection ModelSimon Leiris, Alicia Coelho, Jérôme Castandet, et al.
Journal of Medicinal Chemistry|July 15, 2016
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic DrugsChiara Borsari, Rosaria Luciani, Cecilia Pozzi, et al.
Elife|December 7, 2022
Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growthLuca Costantino, Stefania Ferrari, Matteo Santucci, et al.
ACS Omega|October 7, 2017
Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To Inhibit <i>Trypanosoma brucei</i> Pteridine Reductase in Support of Early-Stage Drug DiscoveryPasquale Linciano, Alice Dawson, Ina Pöhner, et al.
SLAS Discovery : Advancing Life Sciences R & D|February 21, 2019
Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery PlatformCarolina B Moraes, Gesa Witt, Maria Kuzikov, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Antimicrobial Agents and Chemotherapy|December 25, 2019
VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in <i>Enterobacterales</i> and Pseudomonas aeruginosaJodie C Hamrick, Jean-Denis Docquier, Tsuyoshi Uehara, et al.
Journal of Medicinal Chemistry|December 11, 2020
Discovery of <b>ANT3310</b>, a Novel Broad-Spectrum Serine β-Lactamase Inhibitor of the Diazabicyclooctane Class, Which Strongly Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacterales and <i>Acinetobacter baumannii</i>David T Davies, Simon Leiris, Magdalena Zalacain, et al.
Journal of Medicinal Chemistry|November 30, 2022
Optimization of 1,2,4-Triazole-3-thiones toward Broad-Spectrum Metallo-β-lactamase Inhibitors Showing Potent Synergistic Activity on VIM- and NDM-1-Producing Clinical IsolatesAlice Legru, Federica Verdirosa, Yen Vo-Hoang, et al.
ACS Infectious Diseases|August 14, 2020
ANT2681: SAR Studies Leading to the Identification of a Metallo-β-lactamase Inhibitor with Potential for Clinical Use in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing <i>Enterobacteriaceae</i>David T Davies, Simon Leiris, Nicolas Sprynski, et al.
ACS Infectious Diseases|November 15, 2018
SAR Studies Leading to the Identification of a Novel Series of Metallo-β-lactamase Inhibitors for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections That Display Efficacy in an Animal Infection ModelSimon Leiris, Alicia Coelho, Jérôme Castandet, et al.
Journal of Medicinal Chemistry|July 15, 2016
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic DrugsChiara Borsari, Rosaria Luciani, Cecilia Pozzi, et al.
Elife|December 7, 2022
Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growthLuca Costantino, Stefania Ferrari, Matteo Santucci, et al.
ACS Omega|October 7, 2017
Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To Inhibit <i>Trypanosoma brucei</i> Pteridine Reductase in Support of Early-Stage Drug DiscoveryPasquale Linciano, Alice Dawson, Ina Pöhner, et al.
SLAS Discovery : Advancing Life Sciences R & D|February 21, 2019
Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery PlatformCarolina B Moraes, Gesa Witt, Maria Kuzikov, et al.
Pageof 7